My group's research demonstrates that microvascular endothelial cell behaviour is a key regulator of tissue microenvironments, influencing organ function, immune surveillance, and the balance between regeneration and pathological remodelling.

We have shown that this vascular control is particularly important in the context of cancer, where it can dictate both susceptibility to metastatic colonisation and the development of long-term morbidity. Changes in endothelial cell phenotype, whether driven by the tumour, systemic inflammation, hypoxia, or cancer therapies, can reprogramme the microvasculature in organ-specific fashion, altering oxygen handling, metabolic activity, and immune–stromal interactions.

These processes are relevant not only to metastatic spread but also to chronic tissue inflammation, impaired regeneration, and functional decline in organs such as the heart, lung, and brain following cancer or its treatment.

Using a combination of animal models, primary endothelial cell cultures, and molecular and metabolic profiling, we dissect the physiological, cellular, and molecular pathways by which microvascular health governs tissue homeostasis.

Our goal is to identify vascular targets that preserve microvascular health, promoting tissue regeneration, recovery, and long-term organ function across health and disease.